11:51 PM EDT, 09/13/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Tagrisso maintained a significant overall survival benefit eight years after surgery in patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, or EGFRm NSCLC. The updated exploratory data from the phase 3 Adaura trial, which evaluated the drugmaker's Tagrisso as an adjuvant treatment for EGFRm NSCLC after complete tumor resection, were presented on Monday, according to a same-day release. Following an eight-year follow-up, data showed that Tagrisso cut the risk of death by 47% versus placebo among patients with stage II-IIIA EGFRm NSCLC, with an overall survival hazard ratio of 0.53. In the overall trial population, the risk of death was reduced by 48%, with a hazard ratio of 0.52. Meanwhile, an estimated 74% of patients in the primary population who received Tagrisso remained alive after eight years, compared with 58% of those receiving placebo. In the overall trial population, the estimated eight-year survival rate was 79% for Tagrisso versus 64% for placebo.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.